Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8086)	12/19/1998 1:32:00 PM
From: Tharos	Respond to of 17367

procalcitonin.com PCT (Procalcitonin) is an innovative and highly specific marker for the diagnosis of severe bacterial infections and sepsis. PCT supports the lifesaving decision in clinical settings which could direct an effective therapy at the right time and save unnecessary spending for critically ill patients. BRAHMS Diagnostica GmbH offers the LUMItest® PCT test kit, an immunoluminometric assay for the quantitative determination of PCT in human serum and plasma. The procalcitonin website is intended to introduce physicians, researchers and members of the scientific community to presently known experiences with PCT. This page is dedicated to Prof. Claude Bohuon / Paris, the inventor of PCT as an ideal sepsis marker. The PCT measurements are made using a "sandwich" type luminescence immunoassay and a coated-tube technique. The LUMItest® PCT assay uses two monoclonal antibodies that are directed against the C-terminal and mid-regional catacalcin sequences.[emhp mine] The anti-catacalcin antibody is immobilized on the surface of the coated tube, and the anti-calcitonin antibody is labelled using a luminescent acridine derivative. Note: LUMItest® PCT is for research use only in U.S.A. and Japan

To: aknahow who wrote (8086)	12/19/1998 1:52:00 PM
From: Tharos	Respond to of 17367

Seem to remember some moronic post about sepsis and its complexity. Poster used 1994 info, suggesting time stood still in the research community and sepsis was still way beyond anyone's ability to figure out. Found these meetings. Judging from the topics, research continues and the researchers are much closer than they were in 1994. 7th OFA Meeting Organ Failure Academy meeting in memory of Roger Bone November 20-21, 1998 Biohumoral aspects of sepsis Inflammation: too little is bad, enough is necessary, too much is a disaster. Can we control it ? Can we differentiate the phases of pro- and anti-inflammatory cytokines ? Molecular biology and sepsis: procalcitonin, adhesion molecules, heat shock protein and others Delayed neutrophil apoptosis and its role in systemic inflammation The 1998 password is "untimely apoptosis" Injury inflammation and sepsis. A progression of endocrine and metabolic events during organ/system failures Baboons and the human being: similarities and differences Genetic predisposition to human sepsis and organ failure Prevention and management of sepsis and MODS Sepsis and MODS Shall we continue to talk about (or use) SIRS in the 21st century ? Does a MODS score help the patient, the doctor or both ? Panel discussion - Early, intermediate and late stages of sepsis and organ dysfunctions The cardiovascular system - How does it adapt ? Is splanchnic perfusion a critical problem in sepsis ? Metabolism and O2 consumption in trauma and sepsis Prevention and treatment of sepsis, MODS, MOF. What is wrong, what is right. Present and future problems Panel - What is clinical relevance ? Well controlled experiments in normal animals Clinical studies in diverse sick patients Endogenous regulation of the inflammatory process Early detection of endotoxins Histamine: is it clinically important ? New and old markers in sepsis - have we made progress in the diagnosis of sepsis ? From TNF through monocytes to the body. Biohumoral and immunomodulation factors in sepsis - do they work ? Intragastric pH (ipH) and PaCO2 monitoring in sepsis Intravenous immunoglobulins: are they helpful ? Interleukins as therapeutic agents (IL-10, IL-11, 12 and 13) Can multiple agents, which reduce morbidity individually, reduce mortality collectively ? spin.it Sepsis, Endotoxemia and Related Disorders IBC's Eighth Annual Conference January 21-22,1999 · Harbor Court Hotel · Baltimore, MD Endotoxin and Inflammation in Experimental Microbial Sepsis Synthetic Endotoxin Antagonists Cytoprotective Properties of Nitric Oxide in Endotoxemia A Meta-Analysis of Previous Clinical Trials of Anti-Inflammatory Agents in Sepsis Ruthenium Nitric Oxide Scavenging Molecules Mechanisms of Kupffer Cell Response to LPS Efficacy of the Local Administration of Antibodies Nitric Oxide Neutralizers for Treatment of Sepsis Synthetic SOD/Catalase Mimics Highly Protective in an ARDS Model Diagnostic Value of Endotoxin Levels ibcusa.com